nnc0519-0130
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 20, 2022 (NCT05363774)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07004322 | Phase 1 | May 26, 2025 | Novo Nordisk |
| NCT06717698 | Phase 2 | Dec 2, 2024 | Novo Nordisk |
| NCT06718998 | Phase 1 | Nov 20, 2024 | Novo Nordisk |
| NCT06642571 | Phase 1 | Oct 15, 2024 | Novo Nordisk |
| NCT06567041 | Phase 1 | Aug 7, 2024 | Novo Nordisk |
| NCT06513104 | Phase 1 | Jul 18, 2024 | Novo Nordisk |
| NCT06370819 | Phase 1 | Apr 15, 2024 | Novo Nordisk |
| NCT06326060 | Phase 2 | Mar 18, 2024 | Novo Nordisk |
| NCT06326047 | Phase 2 | Mar 18, 2024 | Novo Nordisk |
| NCT05870670 | Phase 1 | May 15, 2023 | Novo Nordisk |
| NCT05363774 | Phase 1 | Apr 20, 2022 | Novo Nordisk |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 11 | 11 | 2 | 2022 |
1 organizations
Page 1 / 1